Biovie Inc (BIVI) - Total Liabilities
Based on the latest financial reports, Biovie Inc (BIVI) has total liabilities worth $3.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIVI operating cash flow to assess how effectively this company generates cash.
Biovie Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Biovie Inc's total liabilities have evolved over time, based on quarterly financial data. Check BIVI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Biovie Inc Competitors by Total Liabilities
The table below lists competitors of Biovie Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Energoinstal S.A.
WAR:ENI
|
Poland | zł46.51 Million |
|
Annexin Pharmaceuticals AB
ST:ANNX
|
Sweden | Skr5.22 Million |
|
Max Resource Corp
V:MAX
|
Canada | CA$2.50 Million |
|
Sirona Biochem Corp
V:SBM
|
Canada | CA$4.27 Million |
|
Calibre
PA:ALWIN
|
USA | €18.95 Million |
|
Superior Resources Ltd
AU:SPQ
|
Australia | AU$522.24K |
|
GPM Metals Inc
V:GPM
|
Canada | CA$430.55K |
Liability Composition Analysis (2013–2025)
This chart breaks down Biovie Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIVI market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biovie Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biovie Inc (2013–2025)
The table below shows the annual total liabilities of Biovie Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $2.55 Million | -73.71% |
| 2024-06-30 | $9.70 Million | -50.91% |
| 2023-06-30 | $19.76 Million | +20.19% |
| 2022-06-30 | $16.44 Million | +1550.35% |
| 2021-06-30 | $996.37K | -95.77% |
| 2020-06-30 | $23.58 Million | +5217.61% |
| 2019-06-30 | $443.48K | -78.52% |
| 2018-06-30 | $2.06 Million | +71.04% |
| 2017-06-30 | $1.21 Million | +50.25% |
| 2016-06-30 | $803.25K | +148.22% |
| 2015-06-30 | $323.60K | +100.40% |
| 2014-06-30 | $161.47K | +976.50% |
| 2013-06-30 | $15.00K | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more